Skip to content

Trial Summary

This phase II/III trial is evaluating different targeted therapy and immunotherapy treatments in patients with advanced or metastatic Non-Small Cell (NSC) Lung Cancer.

Acronym:

BFAST

ACTRN/NCT /ethics:

NCT03178552

Scientific title:

A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)

Sponsor / Cooperative group:

Hoffmann-La Roche

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhasePhase II, Phase III
Age Range18 years and older
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2017-09-22
Anticipated End Date2021-09-18

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Nimit Singhal
Recruitment StatusRecruiting